Asunaprevir

Phase 3Small molecule

Bristol-Myers Squibb

Asunaprevir is one of 97 small molecule programs targeting Kidney Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney DiseaseActive, not recruiting

Chronic HepatitisActive, not recruiting

Hepatitis CActive, not recruiting

Kidney DiseasePhase 1

Active, not recruiting

Chronic HepatitisPhase 3

Active, not recruiting

Hepatitis CPhase 2

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Sovaldi

Gilead

Preclinical

34 3

Asunaprevir

Bristol-Myers Squibb

Phase 3

4 4

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 5

Incivek

Vertex Pharmaceuticals

Preclinical

10 6

Intron a

Sanofi

Preclinical

7 7

Roferon-a

Roche

Preclinical

3 8

Medrol

Pfizer

Preclinical

1 9

Dasabuvir

AbbVie

Preclinical

7 10

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis4 trials

UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02123654·297 enrolled

A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02496078·207 enrolled

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01973049·202 enrolled

Show 1 more trial

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT01492504·1,850 enrolled

Phase II3 trials

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01581203·748 enrolled

Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01995266·218 enrolled

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01573351·398 enrolled

ACL2 trials

Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV

Completed·KKaohsiung Medical University Chung-Ho Memorial Hospital·Phase 3·NCT03004625·70 enrolled

A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02323594·88 enrolled

Kidney Disease1 trial

Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01886599·48 enrolled

Chronic1 trial

Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients

Completed·FFoundation for Liver Research·Phase 3·NCT02282709·12 enrolled

3 more indications

TED1 trial

Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

Completed·AANRS, Emerging Infectious Diseases·Phase 2·NCT02107365·60 enrolled

Hepatitis C1 trial

Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01428063·276 enrolled

Combination Therapy1 trial

A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01718145·258 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Asunaprevir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Asunaprevir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Asunaprevir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Asunaprevir

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Hepatitis4 trials

Phase II3 trials

ACL2 trials

Kidney Disease1 trial

Chronic1 trial

TED1 trial

Hepatitis C1 trial

Combination Therapy1 trial

References

Drug Info

Quick Facts

Related News